Search - tctmd.com

Displaying 581 - 600 of 926

Sort: Relevancy | Date

News Daily News

One in Five Acute MI Patients Drop Statins Within 2 Years

Michael O'Riordan

April 20, 2017

News Daily News

Midlife Vascular Risk Factors Linked to Amyloid Plaques in Alzheimer’s

Alison Palkhivala

April 11, 2017

News Daily News

MR CLEAN: Sustained Benefit of Endovascular Therapy for Acute Ischemic Stroke

Michael O'Riordan

April 05, 2017

News Daily News

Using Coronary CTA to Evaluate Suspected CAD May Improve Patient Outcomes

Todd Neale

April 03, 2017

News Conference News ACC 2017

High-Dose Atorvastatin Does Not Impact Cognition, but Small Changes Observed on Brain MRI

Michael O'Riordan

March 21, 2017

Presentation ACC 2017

EBBINGHAUS: A Cognitive Study of Patients Enrolled in the FOURIER Trial

Presenter: Robert Giugliano

March 19, 2017

News Conference News ACC 2017

Going to Low LDL Levels With Evolocumab Does Not Affect Memory, Brain Function: EBBINGHAUS

Michael O'Riordan

March 19, 2017

News Conference News ACC 2017

VISION: High-Sensitivity Troponin Strongly Linked to Increased Death From Myocardial Injury After Noncardiac Surgery

L.A. McKeown

March 19, 2017

News Conference News ACC 2017

FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo

Michael O'Riordan

March 17, 2017

Presentation ACC 2017

Further cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk

Presenter: Marc Sabatine

March 17, 2017

News Daily News

Timing and Dose Matters When It Comes to Statin Therapy Before CABG Surgery

Michael O'Riordan

March 16, 2017

News Daily News

‘Hub and Spoke’ Model Promises to Improve Access to PCI for STEMI in Low- and Middle-Income Countries

L.A. McKeown

March 14, 2017

News Daily News

Statin-Intolerant Patients Have Significantly Worse Prognosis After MI

Michael O'Riordan

March 13, 2017

News Conference News ACC 2017

ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More

Shelley Wood

March 10, 2017

News Conference News ACC 2017

Low HDL Cholesterol Common in Young MI Patients, With Young Women Faring Worse Long-Term

Michael O'Riordan

March 10, 2017

News Conference News ISC 2017

Early Statin Therapy Fails to Boost Acute Stroke Outcomes, but Trial Methods Questioned

Todd Neale

February 24, 2017

News Conference News ISET 2017

Gains in Carotid Stenting Technology Could Increase the Treatment’s Appeal

Caitlin E. Cox

February 13, 2017

News Daily News

Major CVD Outcomes Trial Testing PCSK9 Inhibitor Evolocumab Meets Primary Endpoint

Michael O'Riordan

February 03, 2017

News Daily News

Noncardiac Surgery Riskier After Incomplete vs Complete Revascularization, Observational Study Finds

Yael L. Maxwell

February 01, 2017

News Daily News

How Low Can Cholesterol Go? Safety Not in Limbo for Patients With Very Low LDL on Alirocumab, Study Shows

Yael L. Maxwell

January 31, 2017

Advertisement

One in Five Acute MI Patients Drop Statins Within 2 Years

Midlife Vascular Risk Factors Linked to Amyloid Plaques in Alzheimer’s

MR CLEAN: Sustained Benefit of Endovascular Therapy for Acute Ischemic Stroke

Using Coronary CTA to Evaluate Suspected CAD May Improve Patient Outcomes

High-Dose Atorvastatin Does Not Impact Cognition, but Small Changes Observed on Brain MRI

EBBINGHAUS: A Cognitive Study of Patients Enrolled in the FOURIER Trial

Going to Low LDL Levels With Evolocumab Does Not Affect Memory, Brain Function: EBBINGHAUS

VISION: High-Sensitivity Troponin Strongly Linked to Increased Death From Myocardial Injury After Noncardiac Surgery

FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo

Further cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk

Timing and Dose Matters When It Comes to Statin Therapy Before CABG Surgery

‘Hub and Spoke’ Model Promises to Improve Access to PCI for STEMI in Low- and Middle-Income Countries

Statin-Intolerant Patients Have Significantly Worse Prognosis After MI

ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More

Low HDL Cholesterol Common in Young MI Patients, With Young Women Faring Worse Long-Term

Early Statin Therapy Fails to Boost Acute Stroke Outcomes, but Trial Methods Questioned

Gains in Carotid Stenting Technology Could Increase the Treatment’s Appeal

Major CVD Outcomes Trial Testing PCSK9 Inhibitor Evolocumab Meets Primary Endpoint

Noncardiac Surgery Riskier After Incomplete vs Complete Revascularization, Observational Study Finds

How Low Can Cholesterol Go? Safety Not in Limbo for Patients With Very Low LDL on Alirocumab, Study Shows

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content